408 related articles for article (PubMed ID: 28750119)
21. Importance of Minimal Residual Disease in the Era of Targeted Therapies in Chronic Lymphocytic Leukemia.
Al-Sawaf O
Acta Haematol; 2024; 147(1):22-32. PubMed ID: 37903476
[TBL] [Abstract][Full Text] [Related]
22. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.
Stilgenbauer S; Eichhorst B; Schetelig J; Hillmen P; Seymour JF; Coutre S; Jurczak W; Mulligan SP; Schuh A; Assouline S; Wendtner CM; Roberts AW; Davids MS; Bloehdorn J; Munir T; Böttcher S; Zhou L; Salem AH; Desai M; Chyla B; Arzt J; Kim SY; Verdugo M; Gordon G; Hallek M; Wierda WG
J Clin Oncol; 2018 Jul; 36(19):1973-1980. PubMed ID: 29715056
[TBL] [Abstract][Full Text] [Related]
23. Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL.
Wierda WG; Kipps TJ; Al-Sawaf O; Chyla B; Biondo JML; Mun Y; Jiang Y; Seymour JF
Leuk Lymphoma; 2022 Dec; 63(12):2765-2784. PubMed ID: 35983732
[TBL] [Abstract][Full Text] [Related]
24. Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease.
Stumpf J; Al-Sawaf O
Curr Oncol Rep; 2024 Feb; 26(2):136-146. PubMed ID: 38175465
[TBL] [Abstract][Full Text] [Related]
25. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia.
Letestu R; Dahmani A; Boubaya M; Baseggio L; Campos L; Chatelain B; Debliquis A; Drénou B; Jacob MC; Legac E; Le Garff-Tavernier M; Lhoumeau AC; Quiney C; Robillard N; Ticchioni M; Aanei C; Katsahian S; Delepine R; Vaudaux S; Rouillé V; Béné MC; Dartigeas C; Van Den Neste E; Leprêtre S; Feugier P; Cartron G; Leblond V; Lévy V; Cymbalista F;
Leukemia; 2021 Jun; 35(6):1597-1609. PubMed ID: 32934355
[TBL] [Abstract][Full Text] [Related]
27. A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia?
Ghia P
Hematology Am Soc Hematol Educ Program; 2012; 2012():97-104. PubMed ID: 23233566
[TBL] [Abstract][Full Text] [Related]
28. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Brown JR; Hallek MJ; Pagel JM
Am Soc Clin Oncol Educ Book; 2016; 35():e387-98. PubMed ID: 27249745
[TBL] [Abstract][Full Text] [Related]
29. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.
Strati P; Keating MJ; O'Brien SM; Burger J; Ferrajoli A; Jain N; Tambaro FP; Estrov Z; Jorgensen J; Challagundla P; Faderl SH; Wierda WG
Blood; 2014 Jun; 123(24):3727-32. PubMed ID: 24705492
[TBL] [Abstract][Full Text] [Related]
30. Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax.
Fürstenau M; Weiss J; Giza A; Franzen F; Robrecht S; Fink AM; Fischer K; Schneider C; Tausch E; Stilgenbauer S; Ritgen M; Schilhabel A; Brüggemann M; Eichhorst B; Hallek M; Cramer P
Clin Cancer Res; 2022 Oct; 28(19):4203-4211. PubMed ID: 35594173
[TBL] [Abstract][Full Text] [Related]
31. Venetoclax: A Review in Previously Untreated Chronic Lymphocytic Leukaemia.
Blair HA
Drugs; 2020 Dec; 80(18):1973-1980. PubMed ID: 33201424
[TBL] [Abstract][Full Text] [Related]
32. Minimal residual disease is an independent predictor for 10-year survival in CLL.
Kwok M; Rawstron AC; Varghese A; Evans PA; O'Connor SJ; Doughty C; Newton DJ; Moreton P; Hillmen P
Blood; 2016 Dec; 128(24):2770-2773. PubMed ID: 27697770
[TBL] [Abstract][Full Text] [Related]
33. Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.
Kater AP; Kersting S; van Norden Y; Dubois J; Dobber JA; Mellink CH; Evers LM; Croon-de Boer F; Schreurs J; van der Spek E; Visser H; Idink C; Wittebol S; Hoogendoorn M; Tonino SH; Mobasher M; Levin MD;
Blood Adv; 2018 Dec; 2(24):3566-3571. PubMed ID: 30552161
[TBL] [Abstract][Full Text] [Related]
34. The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia.
Vitale C; Ferrajoli A
Expert Rev Hematol; 2020 Aug; 13(8):885-894. PubMed ID: 32700593
[TBL] [Abstract][Full Text] [Related]
35. Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.
Owen C; Christofides A; Johnson N; Lawrence T; MacDonald D; Ward C
Leuk Lymphoma; 2017 Dec; 58(12):2777-2785. PubMed ID: 28509580
[TBL] [Abstract][Full Text] [Related]
36. Relevance of Minimal Residual Disease in the Era of Targeted Agents.
Heltai S; Ghia P; Scarfò L
Cancer J; 2019; 25(6):410-417. PubMed ID: 31764122
[TBL] [Abstract][Full Text] [Related]
37. Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
Del Giudice I; Raponi S; Della Starza I; De Propris MS; Cavalli M; De Novi LA; Cappelli LV; Ilari C; Cafforio L; Guarini A; Foà R
Front Oncol; 2019; 9():689. PubMed ID: 31555576
[TBL] [Abstract][Full Text] [Related]
38. Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia.
Molica S; Allsup D; Gianfelici V; Levato L; Aiello V; Bailey J; Polliack A
Expert Opin Investig Drugs; 2021 Jun; 30(6):621-633. PubMed ID: 33929928
[No Abstract] [Full Text] [Related]
39. Eradication of minimal residual disease in chronic lymphocytic leukemia.
Schweighofer CD; Hallek M; Wendtner CM
Curr Hematol Malig Rep; 2008 Jan; 3(1):54-60. PubMed ID: 20425447
[TBL] [Abstract][Full Text] [Related]
40. High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Mauro FR; Starza ID; Messina M; Reda G; Trentin L; Coscia M; Sportoletti P; Orsucci L; Arena V; Casaluci GM; Marasca R; Murru R; Laurenti L; Ilariucci F; Stelitano C; Mannina D; Massaia M; Rigolin GM; Scarfò L; Marchetti M; Levato L; Tani M; Arcari A; Musuraca G; Deodato M; Galieni P; Patrizi VB; Gottardi D; Liberati AM; Giordano A; Molinari MC; Pietrasanta D; Mattiello V; Visentin A; Vitale C; Albano F; Neri A; De Novi LA; De Propris MS; Nanni M; Del Giudice I; Guarini A; Fazi P; Vignetti M; Piciocchi A; Cuneo A; Foà R
Haematologica; 2023 Aug; 108(8):2091-2100. PubMed ID: 36632738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]